J-M Michot (@MichotJM) header
J-M Michot (@MichotJM) profile picture

J-M Michot

@MichotJM

Internal Medicine pract. at Gustave Roussy, in Early Drug Unit. News therapies solutions to be proposed to all pts with hard-to-treat diseases. Tweet my owns.

 Paris, France
Joined April 2017
  • Tweets45
  • Following146
  • Followers132
De l’or plein les yeux pour les enfants hospitalisés de @GustaveRoussy grâce à la @PAFofficiel, marraine d’@ImagineforMargo 🤩 Mille mercis à la #PatrouilleDeFrance pour ce moment exceptionnel offert aux enfants et aux soignants de Gustave Roussy ❤️ #SeptembreEnOr
3
72
16
224
Proteomics (1463 prots) identified LIF levels in the plasma as biomarker of resistance to anti-PD1 Ab. Findings validated in an independant cohort of 292 pts. Circulating LIF correlated with 3ry lymphoid structures in tumor. A study from @GustaveRoussy annalsofoncology.org/article…
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of...

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of...

Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel and reliable...

annalsofoncology.org
9
37
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study ow.ly/KsVj50ExNMi
Image from Blood Journals Portfolio (@BloodPortfolio)
9
2
22
J-M Michot retweeted
soria (@jsoriamd) profile picture
soria
@jsoriamd26 Apr 2021
Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options nature.com/articles/s41571-0…
Image from soria (@jsoriamd)
46
6
162
#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon The authors of excli.de/index.php/excli/art… studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study. @Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad
Image from EXCLI Journal (@EXCLIJournal)
1
1
#VACCINATION #antiCOVID19 Les points essentiels pour les personnes ayant ou ayant eu un #lymphome Mise à jour au 11 février 2021 – at Lyon, France
Image from ELLyE l’Association #Lymphomes #LLC (@AssoELLyE)
11
12
J-M Michot retweeted
The Lancet (@TheLancet) profile picture
The Lancet
@TheLancet9 Feb 2021
2 years ago, we published a special theme issue, #LancetWomen, highlighting how gender bias has stalled women’s advancement in science, medicine, and🌎health. Today, we highlight key milestones and reinforce our commitment to #genderequality.
Lancet Women theme issue cover.

ALT Lancet Women theme issue cover.

3
151
12
350
Complètement fou ! 🤩 Charlie et APIVIA franchissent la ligne d'arrivée du @VendeeGlobe à la première place au terme d'une course dingue. Un seul mot ce soir : MERCI Charlie ! 🙏 @ApiviaMutuelle | @Apivia_courtage | @MacifAssurances
Image from Imoca MACIF Santé Prévoyance (@ImocaMacif)
83
256
84
1,204
SDmax captures lymphoma dissemination. SDmax and TMTV are independent prognosticators and identify high-risk DLBCL patients at baseline. A REMARC @LysaLymphoma ancillary analysis by AS Cottereau et al. see our publication at @Annals_Oncolgy doi.org/10.1016/j.annonc.202…
Image from C. Thieblemont (@c_thieblemont)
6
26
J-M Michot retweeted
FabriceAndre (@FAndreMD) profile picture
FabriceAndre@FAndreMD6 Dec 2020
Something is happening on the side of pancreatic cancer (300 000 death per y): PARP inh, Ras Inh, adj therapies, early detect/ctDNA. Transformation is ongoing A top priority for Funding agencies and philanthropies (pourbertrandkamal.fr @FondationARC @DenisBrogniart @ALJ)
6
30
Have you ever heard of anti-ROR1? A new MOA to keep in mind for upcoming #ASH20: VLS-101, ROR1 antibody drug conjugate (ADC) w/MMAE - Phase 1 trial in pts w/recurrent Mantle Cell and #DLBCL & Still small n but impressive results. Congrats, @michaelwangmd
Image from Thilo J. Zander (@ThiloZander)
3
1
12
J-M Michot retweeted
Simon Rule (@rule_simon) profile picture
Simon Rule@rule_simon5 Dec 2020
Looks very good
Toby A. Eyre (@tobyeyre82) profile pictureToby A. Eyre@tobyeyre825 Dec 2020
.@michaelwangmd et al #loxo-305 in R/R NHL phase I/II No DLTs or MTD reached 3 prior lines - high risk pts Post BTKi ORR in 56 MCL 52% v minimal toxicity longer fup for DoR needed WM ORR v promising 68% post BTKi Global Phase III in R/R MCL planned #lymsm #ASH20
Image from Toby A. Eyre (@tobyeyre82)
Image from Toby A. Eyre (@tobyeyre82)
Image from Toby A. Eyre (@tobyeyre82)
Image from Toby A. Eyre (@tobyeyre82)
5
4
In @NEJM ➡️ Cancer pts receiving immunosuppressive Rx may shed viable #COVID19 virus for 60 days after infection.👇Quarantine guidelines need revision. Pertinent research with huge implications on our practices. 👉🏻 bit.ly/343Bl5J @mini_kamboj & team @SocietyofMSKCC – at Holladay, UT
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
2
24
6
52
Musa Yilmaz presents results on quizartinib plus decitabine with or without venetoclax in pts w/ r/r FLT3-ITD mutated #AML: clinical outcomes and signaling Cytof profiling from a phase 1B/2 trial #leusm #ASH20
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
4
2
3
So, perhaps trial comparing the doublet vs single agent would be more clinically relevant in the future
Image from Anas Younes, M.D. (@DrAnasYounes)
1
2
10
#Covid19 | #Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. First results of the #CORIMUNO-TOCI open-label randomized controlled trial aphp.fr/contenu/tocilizumab-…
Image from Assistance Publique – Hôpitaux de Paris (AP-HP) (@APHP)
20
246
89
412
Hot off the press
Image from Anas Younes, M.D. (@DrAnasYounes)
4
40
5
54
⚠️ On n'oublie pas les #GestesBarrières ⚠️ Les soignants de @GustaveRoussy vous les rappellent en musique ! Merci à l'équipe du #DITEP pour ce rappel créatif 👏
11
124
19
450
#COVID_19 #COVID19France 🗞️ Une synthèse d'actualités scientifiques liées au #COVID19, réalisée et commentée par des experts de @GustaveRoussy, au 20 mars 2020. A lire ici ⬇️ gustaveroussy.fr/fr/covid-19…
36
2
41
Interview de @ASTuszynski, fondatrice de @CanceratWork ➡️ revivreapresunlymphome.fr/te… #jmls19 #revivreapresunlymphome #wlad
1
3
2
Load more